• Dotmatics announce speaker line-up for User Group Meeting 2014

    Jul 23, 2014, 00:00 AM by Michael Croft
    BISHOP'S STORTFORD, UK - Jul 23, 2014 - ~~Dotmatics, a leading provider of informatics solutions to the pharma, biotech, chemical, agrochemical and academic industries, has released the agenda for their annual User Group Meeting
    Full story
  • DataDirect Networks Joins Global Alliance for Genomics and Health

    Jul 22, 2014, 15:00 PM by Michael Croft
    Santa Clara, Calif.—July 22, 2014 - Powering Over One-Third of the World’s Top SequencingCompanies, DDN Will Contribute Expertise in Data Representation, Storage, Analysis and Security of Genomic Data
    Full story
  • Tute Genomics Biomarker Discovery Platform to Support Brigham Young University’s Alzheimer’s Disease Genetics Research

    Jul 22, 2014, 00:00 AM by Michael Croft
    PROVO, NY, UNITED STATES - Jul 22, 2014 - Tute Genomics Biomarker Discovery Platform to Support Brigham Young University's Alzheimer's Disease Genetics Research Provo, Utah (July 22, 2014)  -- Tute Genomics today announced that its genome annotation and discovery platform will support Brigham Young University's (BYU) efforts to advance Alzheimer's disease genetics research
    Full story
  • Dotmatics Appoints Shikha O’Brien as Vice President of Strategic Sales and Marketing

    Jul 22, 2014, 00:00 AM by Michael Croft
    BISHOP'S STORTFORD, UK - Jul 22, 2014 - ~~Dotmatics, a leading provider of scientific informatics solutions and services, is pleased to announce the appointment of Dr
    Full story
  • Miyachi America Announces Sigma Femtosecond Laser Tube Cutter

    Jul 22, 2014, 00:00 AM by Michael Croft
    MONROVIA, CA - Jul 22, 2014 - Miyachi America Corporation, a leading manufacturer of laser welding, laser marking and micro machining equipment and systems, announces its new Sigma Femtosecond Laser Tube cutting system
    Full story
  • Roche Planning to Stay Out of Acquisitions

    Jul 21, 2014, 12:00 PM by Michael Croft
    Reuters | Roche is staying out of the pharma merger and acquisition fray, the CEO said. "We're sticking to our previous strategy... [of] small acquisitions and partnerships."
    Full story
  • Berry Genomics, Illumina Seek Chinese Regulatory Approval for NIPT

    Jul 21, 2014, 12:00 PM by Michael Croft
    Bio-IT World News Brief | Berry Genomics has chosen Illumina next-generation sequencing (NGS) technology as the platform on which Berry hopes to secure Chinese Food and Drug Administration (CFDA) regulatory approval for clinical applications. The combined "system" is in late stage CFDA testing, the Chinese company says.
    Full story
  • Universal Language: The Pistoia Alliance Takes on Indescribable Biology

    Jul 18, 2014, 10:50 AM by Michael Croft
    Bio-IT World | The Pistoia Alliance received a Best Practices Award at this year's Bio-IT World Conference & Expo for its work on HELM, a project that establishes a standard notation for complex macromolecules that are too large to sketch out atomically, but too heterogeneous to express as chains of RNA or amino acids. The project will aid interoperability across the industry, as pharma companies increasingly rely on strange, hybrid biochemistry in creating new therapeutics.
    Full story
  • Could CRISPR Transform Wild Ecosystems?

    Jul 18, 2014, 10:25 AM by Michael Croft
    Bio-IT World | In a paper published yesterday in the open access journal eLife, George Church and colleagues discuss the potential for "gene drives" that alter the genomes of whole wild populations using CRISPR gene editing technology, and weigh the risks and public interests surrounding such initiatives.
    Full story
  • Cloud Pharmaceuticals Enters R&D Agreement with Myos Corporation to Develop Small Molecules Targeting Sarcopenia and Cachexia

    Jul 17, 2014, 00:00 AM by Michael Croft
    RESEARCH TRIANGLE PARK, NC, UNITED STATES - Jul 17, 2014 - Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, has entered an R&D agreement with MYOS Corporation (“MYOS” or the “Company”) (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance
    Full story
  • Illumina Acquires Regulatory Strategy Consulting Firm

    Jul 16, 2014, 12:00 PM by Michael Croft
    Bio-IT World News Brief | Illumina today announced its acquisition of Myraqa, a consulting firm specializing in the regulatory strategy surrounding in vitro diagnostics, particularly companion diagnostics.
    Full story
  • Novartis Signs On to License Google's Glucose-Monitoring Contact Lenses

    Jul 16, 2014, 09:00 AM by Michael Croft
    New York Times | Google and Novartis have announced a partnership for Novartis to license Google's smart contact lens that could measure a wearer's blood sugar levels.
    Full story
  • David Hall Joins Rho as Principal Investigator of Bioinformatics

    Jul 16, 2014, 00:00 AM by Michael Croft
    CHAPEL HILL, NC, UNITED STATES - Jul 16, 2014 - David Hall Joins Rho as Principal Investigator of BioinformaticsGenome informatics specialist played central role in business development activities resulting in award of more than $40M in federal contracts with bioinformatics and -omics focus Chapel Hill, NC  ̶  DATE  Rho, a contract research organization (CRO) focused on bringing new products to market through a full range of product development services, today announced that David Hall has joined its team as a principal investigator (PI) specializing in bioinformatics at its Research Triangle Park headquarters in North Carolina
    Full story
  • Latest Clinical Conductor Release Debuts First-Ever CTMS Configurations

    Jul 16, 2014, 00:00 AM by Michael Croft
    ROCHESTER, NY, UNITED STATES - Jul 16, 2014 - The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology
    Full story
  • RainDance Technologies Appoints Kathy Ordoñez to Board of Directors

    Jul 16, 2014, 00:00 AM by Michael Croft
    BILLERICA, MA - Jul 16, 2014 - RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the appointment of Kathy Ordoñez to its Board of Directors
    Full story
  • IBM Gains Ground with SoftLayer Cloud

    Jul 15, 2014, 12:00 PM by Michael Croft
    Computerworld | IBM is gaining cloud ground with its SoftLayer product, Big Blue says, reporting 6,000 new customers in the last year and $1.2 billion invested in data centers.
    Full story
  • Transcriptic Launches Molecular, Cell Biology On-Demand Lab

    Jul 15, 2014, 09:00 AM by Michael Croft
    Bio-IT World News Brief | Transcriptic today launched the Transcriptic Platform, their own cloud-based programmable system for defining and executing experimental protocols. The company says the platform can create a 10-fold productivity advantage for researchers working on molecular and cell biology.
    Full story
  • BGI Scientists Expand Reference Genes for Human Microbiome

    Jul 14, 2014, 10:10 AM by Michael Croft
    Bio-IT World | The Beijing Genomics Institute (BGI), China's gene sequencing powerhouse, has released a set of reference genes for the human gut microbiome, in a catalogue that is substantially larger and covers a greater diversity of human populations than any previous resources.
    Full story
  • Illumina Chosen as Service Provider for Genomics England Project

    Jul 14, 2014, 06:00 AM by Michael Croft
    Technology Review | Illumina has been chosen as the "preferred partner" for the UK's 100,000 genomes project. Genomics England chose Illumina to do the sequencing, and said that fewer than five other companies bid for the job.
    Full story
  • Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria

    Jul 14, 2014, 00:00 AM by Michael Croft
    RESEARCH TRIANGLE PARK, NC, UNITED STATES - Jul 14, 2014 - Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today the expansion of its drug design and development program
    Full story